Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Assets: 2022-2024

Historic Other Non-Current Assets for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $721,000.

  • Stoke Therapeutics' Other Non-Current Assets rose 45.95% to $721,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $721,000, marking a year-over-year increase of 45.95%. This contributed to the annual value of $721,000 for FY2024, which is 26.71% up from last year.
  • Per Stoke Therapeutics' latest filing, its Other Non-Current Assets stood at $721,000 for FY2024, which was up 26.71% from $569,000 recorded in FY2023.
  • Stoke Therapeutics' 5-year Other Non-Current Assets high stood at $721,000 for FY2024, and its period low was $569,000 during FY2022.
  • Over the past 3 years, Stoke Therapeutics' median Other Non-Current Assets value was $569,000 (recorded in 2023), while the average stood at $619,667.
  • Data for Stoke Therapeutics' Other Non-Current Assets shows a peak YoY rose of 26.71% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Stoke Therapeutics' Other Non-Current Assets stood at $569,000 in 2022, then remained steady at $569,000 in 2023, then increased by 26.71% to $721,000 in 2024.